Who are Medical abortion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mifepristone and misopristol, Mifepristone + Misoprostol, Mifepristone plus two doses Misoprostol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/medical-abortion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Medical abortion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Medical abortion (Medical abortion) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Progesterone receptor antagonist + prostaglandin analog combination. Area: Reproductive Health / Obstetrics.

marketed Progesterone receptor antagonist + prostaglandin analog combination Progesterone receptor (PR); prostaglandin receptors (EP1, EP2, EP3, FP) Reproductive Health / Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

Medical abortion (Medical abortion) — Reproductive Health Training Center of the Republic of Moldova. Medical abortion uses a combination of mifepristone (a progesterone receptor antagonist) and misoprostol (a prostaglandin analog) to terminate early pregnancy by blocking progesterone signaling and inducing uterine contractions.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Medical abortion TARGET	Medical abortion	Reproductive Health Training Center of the Republic of Moldova	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR); prostaglandin receptors (EP1, EP2, EP3, FP)
mifepristone and misopristol	mifepristone and misopristol	Hadassah Medical Organization	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR) and prostaglandin E1 receptor (EP receptor)
Mifepristone + Misoprostol	Mifepristone + Misoprostol	Gynuity Health Projects	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor)
Mifepristone plus two doses Misoprostol	Mifepristone plus two doses Misoprostol	Planned Parenthood League of Massachusetts	phase 3	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Progesterone receptor antagonist + prostaglandin analog combination class)

Gynuity Health Projects · 1 drug in this class
Hadassah Medical Organization · 1 drug in this class
Planned Parenthood League of Massachusetts · 1 drug in this class
Reproductive Health Training Center of the Republic of Moldova · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Medical abortion — Competitive Intelligence Brief. https://druglandscape.com/ci/medical-abortion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab